Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma.

Abstract

Idiotype protein (Id) secreted by myeloma cells is the best-characterized tumor-specific antigen and is widely used in clinical trials of immunotherapy in B-cell tumors. In this study, we used a myeloma murine model to compare the efficacy of two commonly used vaccines in human trials, Id-keyhole limpet hemocyanin (KLH) protein versus Id-KLH-pulsed DC vaccines in preventing or treating myeloma and priming tumor-specific immune responses. Although both vaccines were able to protect mice from developing myeloma, only the DC vaccine induced therapeutic immunity in tumor-bearing mice. DC vaccinations not only retarded tumor growth but also eradicated established myeloma in 60% of mice. The therapeutic efficacy of the DC vaccine was associated with increased tumor-specific IFN-g and IL-4 T-cell responses and cytolytic activity of splenic T cells. Moreover, the vaccines induced tumor-specific immune responses that protected surviving mice from tumor rechallenge. Thus, our results demonstrate that Id-based DC vaccine but not Id-KLH protein vaccine can be therapeutic to established myeloma. Further studies are needed to optimize methods of DC-based vaccines to improve the efficacy of clinical trials.

• Authors: Siqing Wang, Sungyoul Hong, Michele Wezeman, Jianfei Qian, Jing Yang, Qing Yi
• Journal: Frontiers in bioscience : a journal and virtual library (Front Biosci) Vol. 12 Pg. 3566-75 (May 01 2007) ISSN: 1093-9946 [Print] United States
• PMID: 17485322 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Cancer Vaccines

Topics

• Animals
• Cancer Vaccines (immunology, therapeutic use)
• Dendritic Cells (immunology)
• Flow Cytometry
• Immunity, Cellular
• Male
• Mice
• Mice, Inbred C57BL
• Multiple Myeloma (immunology, prevention & control, therapy)